SLNO - Soleno Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6100
-0.1800 (-10.06%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.7900
Open1.7500
Bid0.48 x 900
Ask1.78 x 800
Day's Range1.6100 - 1.7690
52 Week Range1.5000 - 3.6000
Volume21,347
Avg. Volume50,107
Market Cap34.511M
Beta (3Y Monthly)-0.15
PE Ratio (TTM)N/A
EPS (TTM)-1.02
Earnings DateMar 14, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • Simply Wall St.3 days ago

    Is Soleno Therapeutics, Inc.’s (NASDAQ:SLNO) CEO Pay Justified?

    In 2014 Anish Bhatnagar was appointed CEO of Soleno Therapeutics, Inc. (NASDAQ:SLNO). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...

  • GlobeNewswirelast month

    Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that clinical data from a Phase II study (PC025) of diazoxide choline controlled release (DCCR) investigating the effects of DCCR treatment on hyperphagia and fat loss in patients with Prader-Willi Syndrome (PWS) were delivered today in a poster presentation at the Obesity Society Meeting 2018, taking place this week in Nashville, TN. “While the hallmark characteristic of PWS is hyperphagia, PWS patients also experience ectopic accumulation of body fat, obesity and associated cardiometabolic complications, which is the leading cause of death of PWS patients,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno.

  • GlobeNewswirelast month

    Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results

    REDWOOD CITY, Calif., Nov. 15, 2018 -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the.

  • GlobeNewswire2 months ago

    Soleno Therapeutics Presents Clinical Data on DCCR at 2018 Foundation for Prader-Willi Research Annual Conference

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data supporting a potential mechanism of action paired with phase II data, and clinical safety data of diazoxide choline controlled release (DCCR), supporting the Phase III study design in Prader-Willi Syndrome (PWS), were presented in oral and poster presentations on October 4, 2018, at the 2018 Foundation for Prader-Willi Research Annual Conference (FPWR), in Las Vegas. “The data presented on DCCR at this year’s FPWR continue to support the design of our ongoing Phase 3 trial,” said Anish Bhatnagar M.D., Chief Executive Officer of Soleno Therapeutics.

  • GlobeNewswire2 months ago

    Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that clinical pharmacokinetic and glycemic impact data from studies of Soleno’s lead product candidate, diazoxide chloride controlled release (DCCR) for the treatment of Prader-Willi Syndrome (PWS), were presented as two posters during a late-breaking session on September 29, 2018, at the 57th Annual European Society for Paediatric Endocrinology (ESPE) Meeting in Athens, Greece. “The pharmacokinetic data presented at ESPE clearly demonstrate that DCCR is suitable for once-daily dosing, which is important for patient compliance, particularly in children,” said Anish Bhatnagar M.D., chief executive officer of Soleno Therapeutics.  “In addition, DCCR’s constant intraday circulating drug levels have the potential to reduce the likelihood of adverse events that can be associated with drug level fluctuations.

  • GlobeNewswire3 months ago

    Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease

    REDWOOD CITY, Calif., Sept. 19, 2018-- Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish ...

  • GlobeNewswire3 months ago

    Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinology

    REDWOOD CITY, Calif., Sept. 17, 2018-- Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases will present two poster presentations ...

  • What Should You Know About Soleno Therapeutics Inc’s (NASDAQ:SLNO) Future?
    Simply Wall St.8 months ago

    What Should You Know About Soleno Therapeutics Inc’s (NASDAQ:SLNO) Future?

    The latest earnings update Soleno Therapeutics Inc’s (NASDAQ:SLNO) released in December 2017 suggested that losses became smaller relative to the prrior year’s level – great news for investors Below isRead More...

  • Does Soleno Therapeutics Inc’s (NASDAQ:SLNO) Past Performance Indicate A Weaker Future?
    Simply Wall St.9 months ago

    Does Soleno Therapeutics Inc’s (NASDAQ:SLNO) Past Performance Indicate A Weaker Future?

    When Soleno Therapeutics Inc (NASDAQ:SLNO) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...

  • Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near?
    Simply Wall St.9 months ago

    Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near?

    Soleno Therapeutics Inc’s (NASDAQ:SLNO): Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. With the latest financial year loss of -US$10.39MRead More...